why choose us

Clinical Trials Search

Showing 17,260 of 132,963 result(s)
Muscle Impact of Treating Osteoporosis

Status: Completed

Condition: Sarcopenia

Interventions: Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.

Date: 2022-12-15

Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers

Status: Completed

Condition: Ketones, Metabolism

Interventions: SGTL2i (15 mg) once daily

Date: 2022-12-15

Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders

Status: Completed

Condition: Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa)

Interventions:

Date: 2022-12-15

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

Status: Completed

Condition: Cytomegalovirus

Interventions: single intravenous (IV) infusion.

Date: 2022-12-15

A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device

Status: ACTIVE_NOT_RECRUITING

Condition: Pulmonary Fibrosis

Interventions: A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)?? sensor, with an accompanying mobile application (

Date: 2022-12-15

The Role of Sugammadex in Posotoperative Urinary Retention in Patients Undergoing Pelvic Floor Reconstructive Procedures

Status: Completed

Condition: Postoperative Urinary Retention

Interventions: Sugammadex or G;N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist.
The surgeon will typica

Date: 2022-12-15

Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease

Status: ACTIVE_NOT_RECRUITING

Condition: Parkinson's Disease and Parkinsonism

Interventions: Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system

Date: 2022-12-15

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Status: Completed

Condition: PD-L1-selected Solid Tumors

Interventions: Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).

Date: 2022-12-15